9/11/2024 | BKDDHY | S&P ups Emergent BioSolutions
|
9/6/2024 | BKDDHY | Moody's raises Emergent BioSolutions
|
8/16/2024 | HY | Market Commentary: Junk closes heavy volume week, pipeline expected to dwindle; Prime Healthcare improves
|
7/9/2024 | HY | Market Commentary: Cinemark, Watco price; calendar builds; Brightline improves; Emergent jumps; Ardagh under pressure
|
6/28/2024 | BKDDHY | S&P nicks Emergent BioSolutions
|
5/9/2024 | BKDDHY | Moody's stabilizes Emergent view
|
3/12/2024 | BKDDHY | S&P cuts Emergent BioSolutions
|
8/31/2023 | BKDDHY | S&P cuts Emergent BioSolutions
|
8/22/2023 | BKDDHY | Moody's prunes Emergent BioSolutions
|
3/3/2023 | BKDDHY | Moody's trims Emergent BioSolutions
|
2/16/2023 | HY | Market Commentary: Emergent BioSolutions, CHS notes rally; Coinbase up; Avaya, Lumen, Rite Aid decline
|
2/16/2023 | HY | Market Commentary: Junk: CHS/Community Health active post-earnings; Service Properties, Emergent Bio jump
|
1/9/2023 | BKDDHY | Emergent BioSolutions expects restructuring to save over $60 million
|
12/23/2022 | HY | Market Commentary: Market action thin, volatility down; newcomers to distressed debt space draw attention
|
12/19/2022 | HY | Market Commentary: Revlon trades after plan preview; Sears paper attracts distressed interest; Emergent up
|
11/14/2022 | BKDDHY | Moody's trims Emergent BioSolutions
|
11/10/2022 | BKHY | S&P slices Emergent BioSolutions
|
10/13/2022 | BKHY | Moody’s cuts Emergent BioSolutions
|
5/2/2022 | BKHY | Moody's cuts Emergent BioSolutions
|
11/10/2021 | BKHY | S&P shifts Emergent view to negative
|
4/30/2021 | BKCVHY | Moody's alters Emergent view to negative
|
4/20/2021 | HY | Market Commentary: High yield: Morgan Automotive prices; Jazz megadeal on tap; Charter flat; Emergent down again
|
8/5/2020 | HY | Market Commentary: Howard Hughes, Harvest Midstream, DSLD price; new deals trade up; index turns positive
|
8/4/2020 | HY | Market Commentary: Leviathan, Penske, Emergent, Element, Xerox price; Melco adds on; Service, Apache gain
|
8/4/2020 | HY | New Issue: Emergent BioSolutions sells upsized $450 million 3 7/8% eight-year notes at par
|
8/4/2020 | BKCVHY | Moody’s gives Emergent BioSolutions Ba2, notes Ba3
|
8/4/2020 | BKCVHY | S&P rates Emergent BioSolutions BB, notes BB-
|
8/4/2020 | HY | Emergent BioSolutions expected to price $400 million eight-year notes on Wednesday
|